CHU de Rouen - Hôpital Charles Nicolle
- Address
- lock Available on a paid plan
CHU de Rouen - Hôpital Charles Nicolle: Advanced Oncology Research
CHU de Rouen - Hôpital Charles Nicolle serves as a leading center for cancer research, with particular expertise in thoracic malignancies and rare pediatric tumors. The institution conducts sophisticated clinical trials investigating both surgical and systemic treatment approaches for patients with challenging oncologic diagnoses.
- Non-small cell lung cancer adjuvant immunotherapy trials using PD-L1 targeted agents
- Ewing sarcoma multimodal treatment optimization including chemotherapy and radiotherapy protocols
- Phase III randomized controlled studies in completely resected thoracic malignancies
The center demonstrates significant commitment to international collaborative research, particularly in the development of personalized treatment strategies based on biomarker expression. Their participation in complex protocols combining surgical resection, chemotherapy, and radiotherapy reflects expertise in managing both common and rare cancers. The institution's involvement in pediatric oncology research, specifically Ewing sarcoma, and advanced lung cancer immunotherapy trials positions it as a comprehensive oncology research facility with capabilities spanning multiple age groups and disease presentations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 16 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CHU de Rouen - Hôpital Charles Nicolle
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase III Double-Blind, Placebo-Controlled Study of Adjuvant Durvalumab in Resected Stage IB-IIIA Non-Small Cell Lung Cancer with PD-L1 Expression ≥25% | Clinipace Global Limited, Fundacion GECP, Intergroupe Francophone De Cancerologie Thoracique, NVALT-studies Stichting, Queen's University | Phase III | Not Recruiting | Mar 2015 | Mar 2025 |
IMP list
lock Showing 1 of 16 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Capecitabine | 3 | Unknown | 2014-12-23 | 2023-06-23 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.